Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients  

作　　者：Guo-ping YANG Hong YUAN Bin TANG Wei ZHANG Lian-sheng WANG Zhi-jun HUANG Dong-sheng OU-YANG Gui-xiang ZHANG Hong-hao ZHOU 

机构地区：[1]Centre of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha 410078, China [2]Department of Cardiovascular Medicine 1, Jiangxi Provincial People's Hospital, Nanchang 330006, China [3]Institute of Clinical Pharmacology, Central South University, Changsha 410078, China

出　　处：《Acta Pharmacologica Sinica》2010年第3期382-386,共5页中国药理学报（英文版）

摘　　要：Aim： To investigate the SLCO1B1 388A〉G and 521T〉CC polymorphisms in hyperlipidemia patients and evaluate the effect of the two polymorphisms on the lipid-lowering efficacy of pitavastatin.Methods： The functional polymorphisms of SLCO1B1 （388A〉G and 521T〉C） were genotyped in 140 Chinese patients with essential hyperlipidemia using polymerase chain reaction-restriction fragment length polymorphism （PCR-RFLP） and one-step tetra-primers ARMS-PCR. Eighty-five patients were enrolled in the clinical trial and given 2 mg of pitavastatin daily for 8 weeks. Total cholesterol （TC）, triglyceride （TG）, high-density lipoprotein （HDL）, and low-density lipoprotein （LDL） serum levels were measured at baseline, after 4 weeks and after 8 weeks of treatment. Results： The allele frequencies of SLCO1B1 388A〉G and 521T〉C in essential hyperlipidemia patients were 71.1% and 11.1%, respectively. The 4- and 8-week treatment with pitavastatin significantly reduced TC, TG, and LDL levels, but there was no statistical difference among patients with wild type, SLCO1B1 388A〉G or SLCO1B1 521T〉C in the lipid-lowering efficacy of pitavastatin.Conclusion： The present study found that the allele frequencies of SLCO1B1 388A〉G and 521T〉C in Chinese patients with essential hyperlipidemia are comparable to those in healthy Chinese population. SLCO1B1 388A〉G and 521T〉C do not affect the lipid-lowering efficacy of pitavastatin.Aim： To investigate the SLCO1B1 388A〉G and 521T〉CC polymorphisms in hyperlipidemia patients and evaluate the effect of the two polymorphisms on the lipid-lowering efficacy of pitavastatin.Methods： The functional polymorphisms of SLCO1B1 （388A〉G and 521T〉C） were genotyped in 140 Chinese patients with essential hyperlipidemia using polymerase chain reaction-restriction fragment length polymorphism （PCR-RFLP） and one-step tetra-primers ARMS-PCR. Eighty-five patients were enrolled in the clinical trial and given 2 mg of pitavastatin daily for 8 weeks. Total cholesterol （TC）, triglyceride （TG）, high-density lipoprotein （HDL）, and low-density lipoprotein （LDL） serum levels were measured at baseline, after 4 weeks and after 8 weeks of treatment. Results： The allele frequencies of SLCO1B1 388A〉G and 521T〉C in essential hyperlipidemia patients were 71.1% and 11.1%, respectively. The 4- and 8-week treatment with pitavastatin significantly reduced TC, TG, and LDL levels, but there was no statistical difference among patients with wild type, SLCO1B1 388A〉G or SLCO1B1 521T〉C in the lipid-lowering efficacy of pitavastatin.Conclusion： The present study found that the allele frequencies of SLCO1B1 388A〉G and 521T〉C in Chinese patients with essential hyperlipidemia are comparable to those in healthy Chinese population. SLCO1B1 388A〉G and 521T〉C do not affect the lipid-lowering efficacy of pitavastatin.

关 键 词：essential hyperlipidemia POLYMORPHISM SLCO1B1 PITAVASTATIN 

分 类 号：Q987[生物学—遗传学] Q78[生物学—人类学]